ATE198748T1 - Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten - Google Patents

Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten

Info

Publication number: ATE198748T1
Authority: AT; Austria
Prior art keywords: fibrinogen receptor; isoxazoline; compounds; receptor antagonists; isoxazole derivatives
Prior art date: 1993-11-24

Application number

AT95901915T

Other languages

English (en)

Inventor

John Wityak

Chu-Biao Xue

Thais Motria Sielecki-Dzurdz

Richard Eric Olson

William Frank Degrado

Gary Avonn Cain

Douglas Guy Batt

Donald Pinto

Original Assignee

Du Pont Pharm Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-11-24

Filing date

1994-11-14

Publication date

2001-02-15

1994-11-14 Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co

2001-02-15 Application granted granted Critical

2001-02-15 Publication of ATE198748T1 publication Critical patent/ATE198748T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT95901915T 1993-11-24 1994-11-14 Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten ATE198748T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US15759893A	1993-11-24	1993-11-24
US23296194A	1994-04-22	1994-04-22
US33792094A	1994-11-10	1994-11-10
PCT/US1994/013155 WO1995014683A1 (en)	1993-11-24	1994-11-14	Novel isoxazoline and isoxazole fibrinogen receptor antagonists

Publications (1)

Publication Number	Publication Date
ATE198748T1 true ATE198748T1 (de)	2001-02-15

Family

ID=27388036

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95901915T ATE198748T1 (de)	1993-11-24	1994-11-14	Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten

Country Status (24)

Country	Link
EP (2)	EP0730590B1 (de)
JP (1)	JPH09505590A (de)
KR (1)	KR100359046B1 (de)
AT (1)	ATE198748T1 (de)
AU (1)	AU695853B2 (de)
BR (1)	BR9408137A (de)
CA (1)	CA2174838A1 (de)
CZ (1)	CZ141996A3 (de)
DE (1)	DE69426604T2 (de)
DK (1)	DK0730590T3 (de)
ES (1)	ES2154326T3 (de)
FI (1)	FI962184A (de)
GR (1)	GR3035610T3 (de)
HR (1)	HRP940952A2 (de)
HU (1)	HUT74690A (de)
IL (1)	IL111721A (de)
NO (1)	NO309768B1 (de)
NZ (1)	NZ276633A (de)
PL (1)	PL182303B1 (de)
PT (1)	PT730590E (de)
RU (1)	RU2149871C1 (de)
SK (1)	SK66696A3 (de)
TW (1)	TW483895B (de)
WO (1)	WO1995014683A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849736A (en) *	1993-11-24	1998-12-15	The Dupont Merck Pharmaceutical Company	Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA963391B (en) *	1995-05-24	1997-10-29	Du Pont Merck Pharma	Isoxazoline fibrinogen receptor antagonists.
US5710159A (en) *	1996-05-09	1998-01-20	The Dupont Merck Pharmaceutical Company	Integrin receptor antagonists
IL118325A0 (en) *	1995-05-25	1996-10-31	Pont Merck And Pharmaceutical	Integrin receptor antagonists and pharmaceutical compositions containing them
DE69633245T2 (de)	1995-09-29	2005-09-08	Eli Lilly And Co., Indianapolis	Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
WO1997015567A1 (de) *	1995-10-20	1997-05-01	Dr. Karl Thomae Gmbh	5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
EP0874629B1 (de) *	1995-12-21	2004-05-19	Bristol-Myers Squibb Pharma Company	ISOXAZOLIN, ISOTHIAZOLIN UND PYRAZOLIN ALS FAKTOR Xa INHIBITOREN
US5939418A (en) *	1995-12-21	1999-08-17	The Dupont Merck Pharmaceutical Company	Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
EP0939757A1 (de) *	1995-12-22	1999-09-08	Dupont Pharmaceuticals Company	Neue integrin-rezeptorantagonisten
US5760028A (en) *	1995-12-22	1998-06-02	The Dupont Merck Pharmaceutical Company	Integrin receptor antagonists
ZA972195B (en) *	1996-03-15	1998-09-14	Du Pont Merck Pharma	Spirocycle integrin inhibitors
AU2421797A (en) *	1996-03-15	1997-10-01	Du Pont Pharmaceuticals Company	Spirocycle integrin inhibitors
WO1997048395A1 (en) *	1996-06-19	1997-12-24	Du Pont Pharmaceuticals Company	Iontophoretic delivery of integrin inhibitors
JP2000516230A (ja) *	1996-08-15	2000-12-05	デュポンファーマシューティカルズカンパニー	Ｉｉｂ／ｉｉｉａ拮抗薬としての環状カルバメート類およびイソオキサゾリジン類
CA2263999A1 (en) *	1996-08-29	1998-03-05	Merck & Co., Inc.	Integrin antagonists
US5900414A (en) *	1996-08-29	1999-05-04	Merck & Co., Inc.	Methods for administering integrin receptor antagonists
US5738647A (en)	1996-09-27	1998-04-14	Becton Dickinson And Company	User activated iontophoretic device and method for activating same
US5797867A (en)	1996-09-27	1998-08-25	Becton Dickinson And Company	Iontophoretic drug delivery system, including method for activating same for attachment to patient
US6187797B1 (en)	1996-12-23	2001-02-13	Dupont Pharmaceuticals Company	Phenyl-isoxazoles as factor XA Inhibitors
US6022977A (en) *	1997-03-26	2000-02-08	Dupont Pharmaceuticals Company	Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
AU6780398A (en) *	1997-03-28	1998-10-22	Du Pont Merck Pharmaceutical Company, The	Heterocyclic integrin inhibitor prodrugs
US6100260A (en) *	1997-04-21	2000-08-08	Sumitomo Pharmaceutical Company, Limited	Isoxazole derivatives
HRP980291A2 (en) *	1997-06-16	1999-04-30	Lin-Hua Zhang	Crystalline roxifiban
SK174699A3 (en) *	1997-06-19	2000-08-14	Du Pont Pharm Co	Inhibitors of factor xa with a neutral p1 specificity group
US5998424A (en)	1997-06-19	1999-12-07	Dupont Pharmaceuticals Company	Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en)	1997-06-20	2002-01-15	Dupont Pharmaceuticals Company	Guanidine mimics as factor Xa inhibitors
US5886191A (en) *	1997-08-18	1999-03-23	Dupont Pharmaceuticals Company	Amidinoindoles, amidinoazoles, and analogs thereof
ZA988735B (en)	1997-10-06	2000-03-23	Du Pont Pharm Co	An efficient method for the conversion of nitriles to amidines.
US6136833A (en) *	1998-01-16	2000-10-24	Dupont Pharmaceuticals Company	Pharmaceutical formulations and process for their preparation
JP2002509924A (ja)	1998-03-27	2002-04-02	デュポンファーマシューティカルズカンパニー	第Ｘａ因子阻害剤としてのジ置換ピラゾリン類およびトリアゾリン類
AU4584199A (en)	1998-06-29	2000-01-17	Du Pont Pharmaceuticals Company	Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US6319937B1 (en) *	1998-11-18	2001-11-20	Dupont Pharmaceuticals Company	Isoxazoline fibrinogen receptor antagonists
US6303609B1 (en)	1998-11-18	2001-10-16	Dupont Pharmaceuticals Company	Isoxazoline fibrinogen receptor antagonists
US6339083B1 (en) *	1998-12-14	2002-01-15	Bayer Aktiengesellschaft	Multiheterocyclic pharmAceuticals
WO2000053168A2 (en) *	1999-03-11	2000-09-14	Du Pont Pharmaceuticals Company	Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders
US6794412B1 (en)	1999-03-11	2004-09-21	Bristol-Myers Squibb Pharma Company	Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
BR0010381A (pt) *	1999-03-11	2002-02-05	Du Pont Pharm Co	Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
CA2368630A1 (en)	1999-04-02	2000-10-12	Ruth R. Wexler	Aryl sulfonyls as factor xa inhibitors
KR20040054803A (ko)	2001-11-26	2004-06-25	제넨테크, 인크.	카테터 조성물 및 그의 용도
EP1677783A2 (de)	2003-10-08	2006-07-12	Nicholas Piramal India Limited	Fibrinogen-rezeptor-antagonisten und ihre verwendung
ES2526614T3 (es)	2004-03-05	2015-01-13	Nissan Chemical Industries, Ltd.	Compuesto de benzamida sustituida con isoxazolina y agente de control de organismos nocivos
US7842815B2 (en)	2004-06-17	2010-11-30	Infinity Pharmaceuticals, Inc.	Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
CN101006065B (zh) *	2004-06-17	2012-07-11	英菲尼蒂发现公司	抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
AU2005295818A1 (en) *	2004-10-12	2006-04-27	Amgen Inc.	Novel B1 bradykinin receptor antagonists
EP1817306A1 (de)	2004-10-13	2007-08-15	Amgen, Inc	Triazole und deren verwendung als bradykinin-b1-rezeptorantagonisten
BRPI0617076B1 (pt)	2005-09-02	2021-07-06	Nissan Chemical Corporation	Composto benzamida substituída por isoxazolina da fórmula (1) ou sal do mesmo; composto benzamida substituido por 4-hidroxiiminametila da fórmula (2) ou sal do mesmo; pesticida; agente agroquímico; parasiticida interno ou externo para mamíferos ou aves; inseticida ou acaricida
TWI403320B (zh)	2005-12-16	2013-08-01	Infinity Discovery Inc	用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
PL1984344T3 (pl)	2005-12-29	2013-03-29	Lexicon Pharmaceuticals Inc	Multicykliczne pochodne aminokwasów oraz sposób ich stosowania
TWI389895B (zh)	2006-08-21	2013-03-21	Infinity Discovery Inc	抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US8916148B2 (en)	2006-11-07	2014-12-23	Genentech, Inc.	Tissue plasminogen activator variant uses
TW201040166A (en) *	2009-04-07	2010-11-16	Astrazeneca Ab	Isoxazol-3(2H)-one analogs as therapeutic agents
US8729263B2 (en)	2012-08-13	2014-05-20	Novartis Ag	1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
AU2014296255B2 (en)	2013-07-31	2017-08-03	Novartis Ag	1,4-disubstituted pyridazine derivatives and their use for treating SMN-deficiency-related conditions
DE102014108210A1 (de)	2014-06-11	2015-12-17	Dietrich Gulba	Rodentizid
AR114489A1 (es)	2018-04-12	2020-09-09	Morphic Therapeutic Inc	ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA
EP4070658A1 (de)	2021-04-06	2022-10-12	BIORoxx GmbH	Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
EP4509511A1 (de)	2023-08-17	2025-02-19	Bayer Aktiengesellschaft	Substituierte spiro-isoxazolinyl-lactame, deren salze und ihre verwendung als herbizide wirkstoffe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99537A (en) *	1990-09-27	1995-11-27	Merck & Co Inc	Fibrinogen receptor antagonists and pharmaceutical preparations containing them
HUT68769A (en) *	1991-05-07	1995-07-28	Merck & Co Inc	FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
DE4124942A1 (de) *	1991-07-27	1993-01-28	Thomae Gmbh Dr K	5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5227490A (en) *	1992-02-21	1993-07-13	Merck & Co., Inc.	Fibrinogen receptor antagonists
JP3240534B2 (ja) *	1992-06-05	2001-12-17	コニカ株式会社	画像形成方法

1994
- 1994-11-14 ES ES95901915T patent/ES2154326T3/es not_active Expired - Lifetime
- 1994-11-14 DE DE69426604T patent/DE69426604T2/de not_active Expired - Fee Related
- 1994-11-14 PL PL94314591A patent/PL182303B1/pl unknown
- 1994-11-14 RU RU96113095/04A patent/RU2149871C1/ru not_active IP Right Cessation
- 1994-11-14 PT PT95901915T patent/PT730590E/pt unknown
- 1994-11-14 EP EP95901915A patent/EP0730590B1/de not_active Expired - Lifetime
- 1994-11-14 SK SK666-96A patent/SK66696A3/sk unknown
- 1994-11-14 BR BR9408137A patent/BR9408137A/pt not_active Application Discontinuation
- 1994-11-14 CA CA002174838A patent/CA2174838A1/en not_active Abandoned
- 1994-11-14 KR KR1019960702749A patent/KR100359046B1/ko not_active IP Right Cessation
- 1994-11-14 EP EP99119541A patent/EP0970950A3/de not_active Withdrawn
- 1994-11-14 AU AU10980/95A patent/AU695853B2/en not_active Ceased
- 1994-11-14 WO PCT/US1994/013155 patent/WO1995014683A1/en not_active Application Discontinuation
- 1994-11-14 NZ NZ276633A patent/NZ276633A/en unknown
- 1994-11-14 JP JP7515117A patent/JPH09505590A/ja active Pending
- 1994-11-14 CZ CZ961419A patent/CZ141996A3/cs unknown
- 1994-11-14 AT AT95901915T patent/ATE198748T1/de not_active IP Right Cessation
- 1994-11-14 DK DK95901915T patent/DK0730590T3/da active
- 1994-11-14 HU HU9601414A patent/HUT74690A/hu unknown
- 1994-11-21 IL IL11172194A patent/IL111721A/xx active IP Right Grant
- 1994-11-22 TW TW083110865A patent/TW483895B/zh not_active IP Right Cessation
- 1994-11-23 HR HR08/337,920A patent/HRP940952A2/hr not_active Application Discontinuation
1996
- 1996-05-23 NO NO962096A patent/NO309768B1/no not_active IP Right Cessation
- 1996-05-23 FI FI962184A patent/FI962184A/fi unknown
2001
- 2001-03-20 GR GR20010400456T patent/GR3035610T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
HU9601414D0 (en)	1996-07-29
DE69426604T2 (de)	2001-05-10
HRP940952A2 (en)	1997-04-30
PL182303B1 (en)	2001-12-31
EP0970950A3 (de)	2000-04-05
SK66696A3 (en)	1996-11-06
IL111721A (en)	2000-06-01
JPH09505590A (ja)	1997-06-03
EP0730590B1 (de)	2001-01-17
TW483895B (en)	2002-04-21
CA2174838A1 (en)	1995-06-01
NO309768B1 (no)	2001-03-26
ES2154326T3 (es)	2001-04-01
NO962096D0 (no)	1996-05-23
FI962184A0 (fi)	1996-05-23
NZ276633A (en)	1998-04-27
KR960705794A (ko)	1996-11-08
EP0970950A2 (de)	2000-01-12
IL111721A0 (en)	1995-01-24
GR3035610T3 (en)	2001-06-29
EP0730590A1 (de)	1996-09-11
NO962096L (no)	1996-05-23
RU2149871C1 (ru)	2000-05-27
WO1995014683A1 (en)	1995-06-01
DK0730590T3 (da)	2001-03-19
PL314591A1 (en)	1996-09-16
AU1098095A (en)	1995-06-13
BR9408137A (pt)	1997-08-12
PT730590E (pt)	2001-05-31
DE69426604D1 (de)	2001-02-22
FI962184A (fi)	1996-05-23
KR100359046B1 (ko)	2003-08-02
CZ141996A3 (en)	1996-11-13
HUT74690A (en)	1997-01-28
AU695853B2 (en)	1998-08-27

Publication	Publication Date	Title
ATE198748T1 (de)	2001-02-15	Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten
DE69629116D1 (de)	2003-08-21	Isoxazoline und isoxazole als fibrinogen-rezeptor-antagonisten
ATE168106T1 (de)	1998-07-15	Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten
DE69632548D1 (de)	2004-06-24	ISOXAZOLIN, ISOTHIAZOLIN UND PYRAZOLIN ALS FAKTOR Xa INHIBITOREN
CL2003002756A1 (es)	2005-02-11	Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia.
ATE186532T1 (de)	1999-11-15	Morpholin und thiomorpholin tachykinin rezeptorantagonisten
ATE178614T1 (de)	1999-04-15	Zyklische verbindungen zur verwendung als inhibitoren des glycoprotein iib/iiia
ATE268337T1 (de)	2004-06-15	C11-carbamate von antibakteriellen makroliden
DK58291D0 (da)	1991-04-02	Krystalinsk stof og dets fremstilling
WO2000029406A3 (en)	2000-07-20	Novel isoxazoline fibrinogen receptor antagonists
WO2005035495A3 (en)	2005-07-07	Fibrinogen receptor antagonists and their use
MX9709081A (es)	1998-01-31	Nuevos antagonistas del receptor fibrinogeno de isoxazolina e isoxazol.
ES8308560A1 (es)	1983-09-16	Procedimiento para preparar 6-fluoro-3-(3-(1-heterociclo)-propil)-1,2-benzoisoxazoles.
DE68922596D1 (de)	1995-06-14	3-(3-Ethyl-1,2,4-oxadiazol-5-yl)-1-azabicycloheptan, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen.

Legal Events

Date	Code	Title	Description
2001-05-15	UEP	Publication of translation of european patent specification
2007-08-15	REN	Ceased due to non-payment of the annual fee